We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Japan's cabinet has endorsed a new survey carried out by its Economic and
Fiscal Policy Department on the future of government spending in the country.
In a sign of growing tension between the two corporate owners of a Lake Forest
drugmaker, Abbott Laboratories is accusing its Japanese partner of charging
excessive prices for ingredients used to make a blockbuster heartburn drug.
Sumitomo Pharmaceuticals announced on June 30 that it has signed a licensing
agreement with Conforma Therapeutics for amrubicin hydrocholoride, Sumitomo
Pharmaceuticals' proprietary antitumor agent.
Shanghai Pharmaceutical (Group) Co Ltd (SPGC) is planning to launch an Initial
Public Offering (IPO) in a bid to raise 2-2.5 bln yuan, followed by a Hong Kong
listing next year, the National Business Daily reported
In a surprise twist to what many considered a done deal, two institutional shareholders
are challenging Shire Pharmaceutical Group's proposed purchase of Transkaryotic
Therapies Inc. of Cambridge for $37 a share, or $1.6 billion, according to filings
yesterday with the US Securities and Exchange Commission.
Procyon Biopharma today announced the successful acquisition of Bioxalis Medica
(Bioxalis), a Montreal-based biopharmaceutical company committed to the discovery
and development of targeted liposomes for cancer treatment and the completion
of a concurrent non-brokered $3,500,000 financing of new cash by way of a private
placement in debentures.